Drug Approval | April 18, 2022
Amneal achieves second U.S. biosimilars approval with Alymsys
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
Momelotinib complements GSK’s existing expertise in haematology, with Sierra Oncology anticipating US regulatory submission in Q2 this year and EU submission in the second half of 2022
The minister exhorted the pharmaceutical sector to prepare a plan for the next 25 years
Through the contract, the company will supply two key GMP intermediates for one of the 'patented drugs' of the innovator pharmaceutical customer
Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases
The peptide-based vaccine induces a t cell-dependent response
The app serves as a single, integrated, personalized customer platform for da Vinci surgeons
An intuitive monitor featuring a patient-tailored approach is now in clinical use in select centres in U.S. and Europe
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
Subscribe To Our Newsletter & Stay Updated
